47
Views
13
CrossRef citations to date
0
Altmetric
Review

Strategies for atrial fibrillation therapy: focusing on IKur potassium channel

, , , &
Pages 1443-1456 | Published online: 06 Dec 2007
 

Abstract

Atrial fibrillation is the most common cardiac arrhythmia associated with heart failure, stroke and mortality. Existing treatment of atrial fibrillation with class I or class III antiarrhythmic agents produces negative feedback on the ventricular repolarisations, which is widely considered as a critical risk factor of Torsades de pointes. The serious side effects hinder the appropriate usage and fair evaluation of these antiarrhythmic agents in clinical trials. Specifically existing in the ventricular, the ultra-rapid delayed rectifier potassium current (IKur), encoded by the Kv1.5 gene, is a crucial determinant of Phase I repolarisation during action potential duration. All evidence suggests that the Kv1.5 gene would be a potent target for the treatment of atrial fibrillation. This review describes the progress of Kv1.5 inhibitors in up-to-date literatures and awarded patents, and the latest information in clinical and preclinical trials.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.